公开(公告)号：US20200370022A1

公开(公告)日：2020-11-26

申请号：US16603264

申请日：2018-04-05

申请人： UNIVERSITE DE BORDEAUX ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE ,  INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) ,  INSTITUT D'OPTIQUE THEORIQUE ET APPLIQUEE ,  INSTITUT BERGONIE ,  UNIVERSITE DE RENNES 1 ,  ETABLISSEMENT FRANCAIS DU SANG ,  CENTRE HOSPITALIER UNIVERSITAIRE (CHU) DE RENNES

发明人： LAURENCE BRESSON-BEPOLDIN ,  SIMON LATOUR ,  ISABELLE MAHOUCHE ,  PIERRE NASSOY ,  KEVIN ALESSANDRI ,  KARIN TARTE ,  FRÉDÉRIC MOURCIN

IPC分类号： C12N5/09 ,  C12N5/00 ,  C12N5/0781 ,  G01N33/50

摘要： The invention relates to a process for preparing cellular microcompartments comprising a hydrogel capsule surrounding a cluster of lymphomatous cells. The invention also relates to such a cellular microcompartment and the use thereof for screening anti-cancer molecules.

公开(公告)号：US20200297799A1

公开(公告)日：2020-09-24

申请号：US16649208

申请日：2018-09-20

申请人： Pfizer Inc. ,  Université Côte d'Azur ,  INSERM (Institut National de la Santé et de la Recherche Médicale) ,  Centre National de la Recherche Scientifique

发明人： Elvire Gouze ,  Stéphanie Garcia

IPC分类号： A61K38/17 ,  A61K9/00 ,  A61P5/00 ,  A61P19/00

摘要： The invention features methods of using SFGFR3 polypeptides to treat abnormal visceral fat deposition and the conditions associated with abnormal visceral fat deposition.

公开(公告)号：US10782304B2

公开(公告)日：2020-09-22

申请号：US15736200

申请日：2016-06-23

申请人： INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) ,  UNIVERSITÉ PAUL SABATIER TOULOUSE III

发明人： Stéphanie Cabantous ,  Faten Koraïchi ,  Gilles Favre

IPC分类号： G01N33/68 ,  G01N33/542 ,  C07K16/18 ,  C40B30/04 ,  G01N33/50 ,  G01N33/533

摘要： The present invention relates to methods and kits for detection protein-protein interactions. In particular, the present invention relates to a method for detecting the binding between a first polypeptide (A) and a second polypeptide (B) in a cell comprising i) providing a cell that expresses (a) a polypeptide (GFP1-9) comprising an amino acid sequence having at least 90% of identity with the amino acid sequence selected from the group consisting of SEQ ID NO: 1-4 (b) a first fusion protein wherein the polypeptide (A) is fused to a polypeptide (GFP10) having an amino an amino acid sequence having at least 90% of identity with the amino acid sequence selected from the group consisting of SEQ ID NO:5-7 (c) a second fusion protein wherein the polypeptide (B) is fused to a polypeptide (GFP11) having an amino an amino acid sequence having at least 90% of identity with the amino acid sequence selected from the group consisting of SEQ ID NO: 8-9 and (d) an intrabody specific for the complex formed by the self-assembly of the first, second and third polypeptides (a), (b) and (c) ii) detecting the fluorescence wherein when the fluorescence is detected it is concluded that the polypeptide (A) binds to polypeptide (B) and wherein the fluorescence is not detected it is concluded that the polypeptides (A) does not bind to polypeptide (B).

公开(公告)号：US10765723B2

公开(公告)日：2020-09-08

申请号：US16361902

申请日：2019-03-22

申请人： INSERM (Institut National de la Santé et de la Recherche Médicale) ,  Assistance Publique—Hopitaux De Paris ,  SORBONNE UNIVERSITE

发明人： David Klatzmann ,  David Saadoun ,  Patrice Cacoub ,  Michèle Rosenzwajg ,  Eliane Piaggio ,  Gilbert Bensimon ,  Claude Bernard

IPC分类号： A61K38/20

摘要： The present invention relates to novel therapies for treating autoimmune and inflammatory diseases. More specifically, the present invention relates to a use of low dose interleukin-2 for the treatment of type I diabetes and other autoimmune and/or inflammatory diseases.

公开(公告)号：US10760135B2

公开(公告)日：2020-09-01

申请号：US16068772

申请日：2016-01-13

申请人： INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) ,  UNIVERSITÉ PAUL SABATIER TOULOUSE III ,  CENTRE HOSPITALIER UNIVERSITAIRE DE TOULOUSE

发明人： Pierre Cordelier ,  Louis Buscail ,  Frédéric Lopez

IPC分类号： C07H21/04 ,  C12Q1/6886 ,  G01N33/574 ,  A61P35/00 ,  A61K31/7068 ,  A61K48/00

摘要： The present invention relates to methods for predicting pancreatic cancer treatment response.

公开(公告)号：US20200262929A1

公开(公告)日：2020-08-20

申请号：US16652079

申请日：2018-10-05

申请人： UNIVERSITE D'AIX-MARSEILLE ,  INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) ,  ASSISTANCE PUBLIQUE HÔPITAUX DE MARSEILLE

发明人： MARCEL BLOT-CHABAUD ,  BENJAMIN GUILLET ,  MARIE NOLLET ,  JIMMY STALIN ,  NATHALIE BARDIN ,  FRANÇOISE DIGNAT-GEORGE

IPC分类号： C07K16/30 ,  A61K51/10 ,  A61P35/00

摘要： The present invention relates to the field of diagnostic and treatment of cancer, particularly melanoma, pancreatic cancer, kidney cancer and colon cancer. In particular, the invention relates to an antibody directed specifically to CD146-positive tumors and its applications, particularly for use as a medicament for the prevention and/or treatment of cancer, for use in a method of diagnostic or prognostic of a cancer, or for use as a radiotracer when labelled with a radioactive element.

公开(公告)号：US10736937B2

公开(公告)日：2020-08-11

申请号：US15537596

申请日：2015-12-22

申请人： INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) ,  UNIVERSITÉ DE DROIT ET DE LA SANTÉ DE LILLE 2 ,  UNIVERSITÉ DE LILLE 1 SCIENCES ET TECHNOLOGIES ,  INSTITUT PASTEUR DE LILLE

发明人： Jean-Claude Sirard ,  Christophe Carnoy ,  François Trottein ,  Rémi Porte

IPC分类号： A61K31/04 ,  A61K38/16 ,  A61P31/04 ,  A61K45/06

摘要： The present invention relates to methods and pharmaceutical compositions for the treatment of bacterial superinfections post-influenza. In particular, the present invention relates to a method of treating a bacterial superinfection post-influenza in a subject in need thereof comprising administering the subject with a therapeutically effective amount of a flagellin polypeptide optionally in combination with at least one antibiotic.

公开(公告)号：US20200232989A1

公开(公告)日：2020-07-23

申请号：US16632402

申请日：2018-07-20

申请人： UNIVERSITE D'AIX-MARSEILLE ,  UNIVERSITE COTE D'AZUR ,  ASSISTANCE PUBLIQUE HÔPITAUX DE MARSEILLE ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE ,  INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE)

发明人： MARCEL BLOT-CHABAUD ,  GILLES PAGES ,  MAEVA DUFIES ,  NATHALIE BARDIN ,  FRANÇOISE DIGNAT-GEORGE

IPC分类号： G01N33/574

摘要： The present invention relates to a method of predicting or monitoring the sensitivity of a subject having a cancer, in particular renal cell carcinoma (RCC) to sunitinib, to a method of selecting an appropriate treatment of cancer, to a method of screening or identifying a compound suitable for improving the treatment of a cancer, and to corresponding kits.

公开(公告)号：US20200181089A1

公开(公告)日：2020-06-11

申请号：US16315930

申请日：2017-07-10

申请人： INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) ,  UNIVERSITÉ DE NICE SOPHIA ANTIPOLIS ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE - CNRS - ,  CHU DE NICE

发明人： Thierry PASSERON ,  Rachid BENHIDA ,  Pascal DAO ,  Gian Marco DE DONATIS ,  Anthony MARTIN

IPC分类号： C07D215/44 ,  C07D413/04 ,  C07D401/04 ,  C07D405/04 ,  A61P35/04

摘要： The present invention relates to a compound of general formula (I): said compound being as defined in claim (1). The invention also relates to a pharmaceutical composition comprising: —a compound of general formula (I) as defined in claim (12) and, —at least one antibody selected from an anti-PD1 antibody, an anti-CTLA4 antibody, an anti-PD-L1 antibody and a mixture of two or more thereof. The invention also relates to a compound of general formula (I) as defined in claim (17) for use in the treatment of cancer, said cancer being preferably selected from melanoma, bladder, kidney, prostate, colon, lung, breast and blood cancer.

公开(公告)号：US10676730B2

公开(公告)日：2020-06-09

申请号：US15542218

申请日：2016-01-06

申请人： INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) ,  UNIVERSITÉ PARIS-SUD

发明人： Olivier Christophe ,  Petrus Lenting ,  Cécile Denis

IPC分类号： C12N9/64 ,  C07K14/75 ,  A61K38/00 ,  C07K14/745

摘要： The present invention relates to mutated factor (FX) polypeptides and uses thereof for the treatment of haemophilia. In particular, the present invention relates to a mutated factor X (FX) polypeptide wherein the heavy chain comprises at least one mutation selected from the group consisting of: —the mutation which consists of the substitution of the glutamic acid residue (E) at position 255 of Seq. ID No. 1 by a glutamine residue (Q), an asparagine residue (N), a serine residue (S), an alanine residue (A), or a tyrosine residue (Y); —the mutation which consists of the substitution of the glutamic acid residue (E) at position 256 of Seq. ID No. 1 by a glutamine residue (Q); and —the mutation which consists of the substitution of the glutamic acid residue (E) at position 258 of Seq. ID No. 1 by a glutamine residue (Q).